X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7593) 7593
Book Review (936) 936
Publication (487) 487
Newspaper Article (156) 156
Newsletter (78) 78
Book Chapter (28) 28
Magazine Article (28) 28
Book / eBook (11) 11
Conference Proceeding (11) 11
Dissertation (8) 8
Trade Publication Article (8) 8
Data Set (3) 3
Paper (2) 2
Transcript (2) 2
Web Resource (2) 2
Government Document (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (6364) 6364
humans (5512) 5512
fasting (4870) 4870
male (4105) 4105
female (3876) 3876
adult (2818) 2818
middle aged (2638) 2638
diabetes (2248) 2248
glucose (2111) 2111
endocrinology & metabolism (1618) 1618
risk factors (1546) 1546
insulin (1507) 1507
aged (1486) 1486
insulin resistance (1319) 1319
blood glucose - metabolism (1305) 1305
animals (1154) 1154
obesity (1121) 1121
type 2 diabetes (1092) 1092
diabetes mellitus (1064) 1064
body mass index (1023) 1023
metabolism (1023) 1023
fasting - blood (936) 936
research (934) 934
analysis (920) 920
health aspects (825) 825
abridged index medicus (822) 822
studies (811) 811
insulin - blood (807) 807
insulin-resistance (794) 794
dextrose (769) 769
cholesterol (762) 762
adolescent (748) 748
young adult (720) 720
blood glucose - analysis (718) 718
risk (717) 717
metabolic syndrome (709) 709
diet (693) 693
hyperglycemia (663) 663
time factors (653) 653
fasting - adverse effects (652) 652
blood pressure (639) 639
pharmacology & pharmacy (623) 623
diabetes mellitus, type 2 - blood (619) 619
medicine (612) 612
physiological aspects (612) 612
diabetes mellitus, type 2 - drug therapy (610) 610
nutrition & dietetics (605) 605
cardiovascular disease (601) 601
body weight (577) 577
lipids (570) 570
care and treatment (567) 567
mortality (566) 566
glucose tolerance test (540) 540
prevalence (537) 537
pregnancy (535) 535
hypertension (530) 530
treatment outcome (530) 530
hypoglycemic agents - therapeutic use (528) 528
clinical trials (507) 507
prospective studies (505) 505
research article (505) 505
patients (489) 489
double-blind method (483) 483
rats (474) 474
mellitus (473) 473
triglycerides - blood (465) 465
glucose metabolism (463) 463
multidisciplinary sciences (451) 451
medicine, general & internal (442) 442
cross-over studies (441) 441
triglycerides (439) 439
cardiovascular-disease (437) 437
internal medicine (437) 437
cardiovascular diseases (433) 433
medicine & public health (426) 426
women (425) 425
mice (424) 424
child (414) 414
fasting - physiology (405) 405
rodents (392) 392
cross-sectional studies (389) 389
disease (388) 388
homeostasis (380) 380
medical research (375) 375
adults (372) 372
impaired fasting glucose (372) 372
nutrition (371) 371
population (369) 369
diabetes-mellitus (368) 368
fasting glucose (367) 367
science (367) 367
food (366) 366
blood (363) 363
physiology (360) 360
lipids - blood (353) 353
blood glucose - drug effects (351) 351
children (350) 350
article (348) 348
blood sugar (348) 348
health risk assessment (346) 346
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7665) 7665
French (63) 63
German (63) 63
Spanish (21) 21
Russian (16) 16
Italian (15) 15
Japanese (13) 13
Danish (8) 8
Polish (8) 8
Chinese (7) 7
Portuguese (7) 7
Czech (4) 4
Hebrew (4) 4
Romanian (4) 4
Korean (3) 3
Swedish (3) 3
Dutch (2) 2
Slovak (2) 2
Turkish (2) 2
Croatian (1) 1
Hungarian (1) 1
Indonesian (1) 1
Persian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes Care, ISSN 0149-5992, 11/2013, Volume 36, Issue 11, pp. 3803 - 3811
Journal Article
BMC Infectious Diseases, ISSN 1471-2334, 09/2018, Volume 18, Issue 1, pp. 485 - 485
Background: Antiretroviral therapy (ART) use in pregnancy presents unquestionable benefits in preventing mother-to-child transmission (MTCT) of HIV although it... 
Pregnancy | Adverse effects | HIV | Toxicity | Antiretroviral therapy | INFECTIOUS DISEASES | METAANALYSIS | SAFETY | MOTHER | PREVENTION | TO-CHILD-TRANSMISSION | PROTEASE INHIBITORS | EFAVIRENZ | COMPLICATIONS | EXPERIENCE | Anti-Retroviral Agents - therapeutic use | Humans | Middle Aged | Anti-Retroviral Agents - adverse effects | CD4 Lymphocyte Count | Young Adult | Liver Diseases - etiology | Adolescent | Brazil | Adult | Female | HIV Infections - drug therapy | Treatment Adherence and Compliance | Dyslipidemias - etiology | Infectious Disease Transmission, Vertical - prevention & control | Anemia - etiology | Pregnancy Outcome | Cohort Studies | Antiviral agents | Control | Disease transmission | Pregnant women | Dosage and administration | Drug therapy | Health aspects | HIV infection | Allergy | Anemia | Liver | Information management | HIV (Viruses) | Allergic reaction | Risk factors | Anemia in pregnancy | Highly active antiretroviral therapy | Complications and side effects | Analysis | Therapy | Nevirapine | Dyslipidemia | Systematic review | Multivariate analysis | Confidence intervals | Hyperbilirubinemia | Acquired immune deficiency syndrome--AIDS | Mathematical analysis | Antiretroviral agents | Human immunodeficiency virus--HIV | Nelfinavir | Thrombocytopenia | Antiretroviral drugs | Data analysis | Fasting | Statistical analysis | Abnormalities | Diabetes mellitus | Lopinavir | Hypersensitivity | Data processing | Regression analysis | Statistical tests | Risk analysis | CD4 antigen | Side effects | Womens health | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10088, pp. 2473 - 2481
Summary Background In blinded randomised controlled trials, statin therapy has been associated with few adverse events (AEs). By contrast, in observational... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | CLINICAL-TRIALS | CARDIOVASCULAR-DISEASE | PREVENTION | RISK | INTOLERANCE | PARTICIPANTS | Hematologic Diseases - chemically induced | Hypolipidemic Agents - adverse effects | Atorvastatin - adverse effects | Double-Blind Method | Nocebo Effect | Humans | Middle Aged | Risk Factors | Male | Treatment Outcome | Atorvastatin - administration & dosage | Sleep Wake Disorders | Early Termination of Clinical Trials | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Lymphatic Diseases - chemically induced | Hypolipidemic Agents - administration & dosage | Hypertension - complications | Adult | Female | Hypercholesterolemia - prevention & control | Aged | Muscular Diseases - chemically induced | Clinical trials | Medicine, Experimental | Complications and side effects | Medical research | Epidemiology | Statins | Analysis | Cardiac patients | Sexual disorders | Risk factors | Myocardial infarction | Heart | Therapy | Laboratories | Funding | Physicians | Disorders | Impairment | Cognitive ability | Lipids | Cardiovascular disease | Angina | Matching | Connective tissues | Disturbance | Heart diseases | Public health | Hypertension | Medical personnel | Lymphatic system | Fasting | Effectiveness | Kidneys | Health risks | Erectile dysfunction | Risk analysis | Patients | Low density lipoprotein | Cholesterol | Doctors | Side effects | Sleep | Atorvastatin | Infarction | Health risk assessment | Cardiovascular diseases | Kidney transplantation | Index Medicus | Abridged Index Medicus | Clinical Medicine | management | clinical-trials | intolerance | risk | cardiovascular-disease | Klinisk medicin | General & Internal Medicine | prevention | participants
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2014, Volume 9, Issue 5, pp. e96368 - e96368
Age and metabolic syndrome are major risk factors for atherosclerosis. However, limited information is available regarding whether cigarette smoking, another... 
INTIMA-MEDIA THICKNESS | MORTALITY | ULTRASONIC MEASUREMENT | ALL-CAUSE | CAROTID ATHEROSCLEROSIS | INSULIN-RESISTANCE | MULTIDISCIPLINARY SCIENCES | DISEASE | FRAMINGHAM RISK SCORE | TOBACCO-SMOKE | CARDIOVASCULAR RISK | Body Mass Index | Smoking - adverse effects | Atherosclerosis - pathology | Age Factors | Carotid Intima-Media Thickness | Humans | Risk Factors | Linear Models | Male | Chi-Square Distribution | Insulin - blood | Metabolic Syndrome - complications | Atherosclerosis - blood | Young Adult | Atherosclerosis - etiology | Carotid Arteries - diagnostic imaging | Fasting - blood | Triglycerides - blood | Aging | Cholesterol, HDL - blood | Adult | Cholesterol, LDL - blood | Female | Blood Glucose - metabolism | Medical research | Smokers | Analysis | Atherosclerosis | Medicine, Experimental | Glucose | Cigarettes | Dextrose | Smoking | Heart | Laboratories | Alcohol | Cardiovascular disease | Metabolic syndrome | Epidemiology | Carotid arteries | Risk factors | Synergistic effects | Ultrasonic imaging | Public health | Age | Young adults | Mortality | Metabolic diseases | Triglycerides | Risk analysis | Cigarette smoking | Insulin | Age factors | Cholesterol | Medicine | Side effects | Lipoproteins | Body mass | Arteriosclerosis | Insulin resistance | Adults | Diabetes | Health risk assessment | Metabolic disorders | Veins & arteries | Index Medicus
Journal Article
Diabetologia, ISSN 0012-186X, 12/2013, Volume 56, Issue 12, pp. 2582 - 2592
The aim of this work was to evaluate the efficacy and safety of canagliflozin vs placebo and sitagliptin in patients with type 2 diabetes who were being... 
Sodium glucose co-transporter 2 (SGLT2) inhibitor | Medicine & Public Health | Human Physiology | Canagliflozin | Metabolic Diseases | Internal Medicine | Sitagliptin | Metformin | Type 2 diabetes mellitus | GLIPIZIDE | ADD-ON | SULFONYLUREA | DAPAGLIFLOZIN | MELLITUS | INADEQUATE GLYCEMIC CONTROL | DIET | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | 52-WEEK | INHIBITOR | Blood Pressure | Triazoles - administration & dosage | Triazoles - adverse effects | Thiophenes - adverse effects | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Pyrazines - administration & dosage | Glycated Hemoglobin A - drug effects | Body Weight - drug effects | Lipids | Male | Thiophenes - administration & dosage | Metformin - adverse effects | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Female | Metformin - administration & dosage | Sitagliptin Phosphate | Drug Therapy, Combination | Glucosides - adverse effects | Fasting | Treatment Outcome | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Glucosides - administration & dosage | Adolescent | Pyrazines - adverse effects | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Care and treatment | Body weight | Glucose | Comparative analysis | Dextrose | Index Medicus
Journal Article
The Lancet, ISSN 0140-6736, 09/2005, Volume 366, Issue 9489, pp. 895 - 906
The apparent shortfall in prevention of coronary heart disease (CHD) noted in early hypertension trials has been attributed to disadvantages of the diuretics... 
MORTALITY | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | MANAGEMENT | MORBIDITY | DISEASE | GUIDELINES | DOUBLE-BLIND | CALCIUM-ANTAGONISTS | HYPERTENSION | INTERVENTION | Calcium Channel Blockers - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Bendroflumethiazide - administration & dosage | Hypertension - drug therapy | Male | Perindopril - administration & dosage | Sodium Chloride Symporter Inhibitors - administration & dosage | Diuretics | Adrenergic beta-Antagonists - adverse effects | Adult | Female | Blood Pressure - drug effects | Atenolol - administration & dosage | Drug Therapy, Combination | Amlodipine - administration & dosage | Adrenergic beta-Antagonists - administration & dosage | Risk Factors | Amlodipine - adverse effects | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Antihypertensive Agents - adverse effects | Coronary Disease - prevention & control | Calcium Channel Blockers - administration & dosage | Atenolol - adverse effects | Hypertension - complications | Aged | Hypertension | Antihypertensive drugs | Evaluation | Dosage and administration | Drug therapy | Prevention | Drug therapy, Combination | Health aspects | Coronary heart disease | Risk factors | Studies | Drugs | Cardiovascular disease | Medical treatment | Myocardial infarction | Heart attacks | Clinical trials | Family medical history | Blood | Randomization | Motivation | Blood pressure | Heart diseases | Antihypertensive agents | Cerebral infarction | Stroke | Fasting | Mortality | Diabetes mellitus | Health risks | Triglycerides | Metabolism | Risk analysis | Atenolol | Fatal | Patients | Coronary artery disease | Cholesterol | Heart rate | Infarction | Diabetes | Cardiovascular diseases | Health risk assessment | Potassium | Index Medicus | Abridged Index Medicus | Amlodipine/administration & dosage/adverse effects | Bendroflumethiazide/administration & dosage | Cardiovascular Diseases/prevention & control | Perindopril/administration & dosage | MEDICIN OCH HÄLSOVETENSKAP | Atenolol/administration & dosage/adverse effects | Combination | Antihypertensive Agents/administration & dosage/adverse effects | Angiotensin-Converting Enzyme Inhibitors/administration & dosage | MEDICAL AND HEALTH SCIENCES | Coronary Disease/prevention & control | Drug Therapy | Adrenergic beta-Antagonists/administration & dosage/adverse effects | Blood Pressure/drug effects | Hypertension/complications/drug therapy | Calcium Channel Blockers/administration & dosage/adverse effects | Sodium Chloride Symporter Inhibitors/administration & dosage
Journal Article